Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) reported a net profit attributable to the shareholders of 344.1 million yuan for the first nine months of the year, a decrease of 12.2% compared with 392.0 million yuan a year ago.
Earnings per share were 0.50 yuan, down from 0.57 yuan in the year-ago period, according to a Tuesday filing with the Hong Kong Stock Exchange.
The company's gross revenue stood at 6.73 billion yuan, a 3.6% increase compared with 6.50 billion yuan a year earlier.
The company's Hong Kong-listed shares were down 3% in the recent trading, while its Chinese shares were down 2%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。